AUTL News and Press, Autolus Therapeutics plc From 05/12/22

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma - AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia - obe-cel: poster presentation in r/r primary CNS lymphoma - obe-cel: poster p...

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2022 Q1 earnings call. For further details see: Autolus Therapeutics plc 2022 Q1 - Results - Earnings Call Presentation

Autolus Therapeutics plc (AUTL) Q1 2022 Earnings Conference Call May 5, 2022 08:30 ET Company Participants Olivia Manser - Director, Investor Relations Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair ...

Autolus Therapeutics press release (NASDAQ:AUTL): Q1 GAAP EPS of -$0.41 beats by $0.07. Revenue of $0.17M (-37.0% Y/Y) in-line. Cash at March 31, 2022, totaled $268.6 million, as compared to $310.3 million at December 31, 2021. Autolus estimates that its current cash on hand and anticipated m...

LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the quarter ended March 31, 2022. “...

Autolus Therapeutics (NASDAQ:AUTL) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.49 (+7.5% Y/Y) and the consensus Revenue Estimate is $0.17M (-37.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revisi...

LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the presentation of three novel cell programming approaches at the American Society of Ge...

The U.S. Food and Drug Administration (FDA) granted regenerative medicine advanced therapy (RMAT) designation to Autolus Therapeutics (NASDAQ:AUTL) gene therapy obecabatagene autoleucel (obe-cel) to treat adult patients with relapsed/refractory B-Acute Lymphocytic Leukemia (ALL), a cance...

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Adva...

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2022 financial results and operational highlight...